ASML enters the back half of May with valuation multiples quietly softening and the stock's sharp Tuesday sell-off cutting across an otherwise positive week — a split that captures the stock's current tension between recovering sector sentiment and lingering earnings-reaction bruises.
The valuation story is the most textured angle this week. Both the P/E and EV/EBITDA multiples have compressed meaningfully over the past 30 days. The P/E has contracted nearly three points to 36.3x. The EV/EBITDA has retreated over three points to 28.1x. That compression has arrived without a dramatic re-rating catalyst — rather, it reflects the stock's flat one-month performance (down 0.3%) even as EPS momentum rankings have nudged higher, now at the 62nd percentile on a 30-day basis. Investors are paying less for each unit of earnings than they were a month ago, even as forward estimate revisions drift modestly upward.
Positioning is almost entirely absent as a pressure point. Short interest is negligible at 0.051% of the free float — there is essentially no active short thesis in the name right now. Borrow availability is effectively unlimited, with the availability ratio running near 9,999%, meaning the lending market is as loose as it gets. Cost to borrow ticked up 25% on the week to 0.79% — but that follows a more than 75% decline over the prior month and remains well below the brief spike to 3.3% seen on April 9 during the tariff-shock episode. The borrow market tells no story about near-term short pressure whatsoever.
Institutional ownership points to steady, if unhurried, accumulation. BlackRock added 204,000 shares in the most recent period to hold 7.2% of the company. Fidelity added 529,000 shares — the largest absolute add among the top 15 holders — bringing its stake to 1.3%. Capital Research added 166,000 shares. These are not dramatic moves, but the direction is consistent and broad-based across passive and active managers alike. The insider picture is routine: February's CEO and CFO sell transactions were paired with same-day award grants, a standard tax-management pattern. A Supervisory Board purchase of 254 shares in mid-February generated the only genuine open-market buy in the recent record. The net 90-day insider value of roughly $17 million positive is largely a function of award timing, not a directional signal.
The recent earnings history carries a clear pattern worth tracking. ASML's Q1 results on April 15 knocked the stock down 4.8% on the day and a further 2.7% over the following five sessions. The subsequent investor day on April 22 brought another 1.1% decline. Both reactions were negative, though modest in the context of a stock that has recovered 3% on the week. The next scheduled earnings date is July 15 — roughly nine weeks away. In the peer group, ASM Pacific fell 5.9% on Tuesday, slightly steeper than ASML's own 3% slide, while US-listed peers Applied Materials and Lam Research both held their losses to around 2.3–2.8%. ACM Research stands out on the week with a 19.3% gain, a divergence worth monitoring as a read on where semis equipment appetite is concentrated. Analyst data available in the dataset predates 2024 and has been omitted as stale.
The setup heading into July is therefore less about positioning pressure — which is absent — and more about whether the valuation reset that has been grinding through May accelerates or stabilises as the macro backdrop around export controls and China demand clarifies ahead of the next earnings print.
See the live data behind this article on ORTEX.
Open ASML on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
